Upon LPS/Nigericin treatment, activation of NLRP3 was the highest in prostate cancer and glioblastoma cells, whilst it was the lowest in the neuroblastoma cell line, SH-SY5Y. The gene discussed is NLRP3; the disease is prostate carcinoma.